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Abstract: This paper aims to present life years at risk (LYAR), a new measure of population 
health needs for primary, secondary and tertiary prevention, which classifies health outcomes 
by care type and distinguishes between positive and negative outcomes. It is determined by 
the  probability  of  ill-health  event,  population  size  and  life  years  lost,  based  on  expected 
incidence, prevalence and mortality. The LYAR consists of two components: the observed 
LYAR, available using disability adjusted life years, and the avoided LYAR. Three examples 
are  given  to  illustrate  the  calculation  and  application  of  the  measure.  The  advantages, 
disadvantages and policy implications are also discussed.  
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1. Introduction 
 
Population health refers to overall level and dispersion of health status in a defined population [1]. 
The  assessment  of  population  health  needs  is  central  to  planning  and  providing  health  services  to 
improve  population  health  and  utilize  health  resources  effectively  and  efficiently  [2].  Improving 
population health means both increasing overall level of health and reducing health gaps by eliminating 
or alleviating health hazards and preventing the occurrence of disease, injury, disability and premature 
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death [3,4]. Accordingly, the purpose of health services can be considered to be loss aversion, and the 
extent of the risk of ill-health in the population indicates the level of needs for health care.  
Healthy life years were proposed as a measure for population health in the 1960s [5], and further 
developments  have  included  health  indices  [6-9],  quality  adjusted  life  years  [10-12]  and  disability 
adjusted life years (DALYs) [13-15]. Of these measures, the DALY has become widely known as the 
standard unit of measure in burden of disease and injury studies (referred to hereafter as burden of 
disease studies). It can also be applied in the economic evaluation of health interventions [16]. The 
DALY  aggregates  the  years  of  life  lost  (YLL)  due  to  premature  death  and  the  years  lost  due  to 
disability (YLD) into a single number. The YLD is calculated on the basis of the duration and severity 
weight of the disability (the relative preference for the disability state compared with full health and 
death) to enable compatibility with YLL [13].  
Although  there  has  been  much  criticism  of  the  DALY  [17-19],  it  represents  a  significant 
improvement in accuracy of health needs measurement, because DALYs combine both fatal and non-
fatal outcomes and change the measurement from counting number of deaths to calculating years of 
healthy life lost [20]. DALYs have been widely used to quantify and compare population health needs 
as an indicator of where resources should be directed to, given the current level of access to health care. 
A recent burden of disease study for Indigenous Australians identified the Indigenous population as 
having a disproportionately large share of total DALYs [21]. While this suggests that they should be a 
priority for health care services, the full extent of their needs is unclear as the DALY only represents the 
negative  health  outcomes  (mortality  and  morbidity)  that  arise  despite  past  and  continuing  health 
investments. The DALY provides no information on the extent of positive health outcomes (avoided 
disease,  injury,  disability  and  death).  The  negative  health  outcomes  are  insufficient  for  resource 
allocation [22]. The inclusion of positive outcomes forms a legitimate part of health needs assessment, 
because  continued  investment  may  be  needed  to  keep  negative  outcomes  low.  For  example,  renal 
dialysis can postpone death for patients with renal failure and reduce DALYs, but it does not mean less 
need for health care. Measuring total health needs would better inform decisions on resource allocation 
and identify whether gaps in health status between sub-groups in the population arise from a lack of 
investment, relative differences in investment or level of access to the services.  
A further limitation of the DALY is its inability to distinguish between needs for different types of 
health care [17,23]. A disease may have a high share of total DALYs, but this does not inform on the 
relative  impact  of  different  care  types.  For  example,  acute  hospital  care  may  provide  medical  and 
surgical acute care to reduce mortality, but more efforts may be needed to prevent the occurrence of the 
disease and disability [24]. Such information could facilitate prioritization between different sectors of 
health care and assist in the comparison of different types of intervention.  
This study seeks to explore the use of the DALY as a measure of relative health needs particularly 
where there are differences in levels of access to health care. The objective of this paper is to present a 
new measure: life years at risk (LYAR) that classifies DALYs in accordance with different health care 
types  from  a  prevention  perspective,  and  incorporates  both  positive  and  negative  health outcomes. 
Examples of the calculation and application of the LYAR are provided, and its limitations and policy 
implications discussed.  Int. J. Environ. Res. Public Health 2009, 6                 
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2. Method 
 
Concepts  from  preventive  medicine  were  used  to  construct  the  LYAR  measure.  From  this 
perspective, health services encompass three types of care: primary prevention, which reduces incidence 
of disease or injury; secondary prevention, which lessens and avoids disability; and tertiary prevention, 
which saves lives and delays deaths [25,26]. Table 1 summarizes the function, target population and 
intervention features for the three types of health care. As a measure of health needs for the three care 
types, the LYAR represents the expected number of healthy life years at risk of disease, injury, disability 
and premature death over a given period of time in a specified population (refer to last column of  
Table 1). 
 
Table 1. Health needs measurement from a prevention perspective. 
Health 
care type  
Health 
care aim 
Target 
population  Intervention features 
Proposed health 
needs measure 
 
Primary 
prevention 
 
Reduce 
incidence 
 
Population at 
risk 
 
Eliminate or alleviate causes, risk factors or 
determinants of the condition; disease 
surveillance; immunization, education, health 
legislation 
 
LYAR of incidence 
of disease or injury  
 
Secondary 
prevention 
 
Reduce 
disability 
 
Patients with 
early stage of 
the condition 
 
Cure disease or mitigate impairments by early 
detection, prompt diagnosis and treatment  
 
LYAR of disability  
 
Tertiary 
prevention  
 
Reduce 
mortality 
 
Patients with 
late stage of 
the condition 
 
Maintain function or prolong survival; life-
saving interventions, surgeries and 
procedures; rehabilitative and palliative care 
 
LYAR of mortality  
Note: LYAR=life years at risk. Modified from Reference [25]. 
 
The LYAR is based on the notion of risk, which combines the probability of an event occurring and 
the consequence of its occurrence [27]. In terms of health, risk can be expressed as the probability of 
illness or injury occurring and the fatal or non-fatal health outcomes from that event [28,29]. Thus, the 
magnitude of the LYAR depends on the proportion of the population falling ill or being injured, the 
level and duration of disability or years of life prematurely lost as a result of those diseases and injuries. 
Thus, the LYAR can be determined quantitatively by 
LYAR = probability of the event  population  expected healthy life years lost due to the event  (1) 
Like  DALYs,  the  expected  values  for  these  variables  can  be  ascertained  from  clinical  and 
epidemiological evidence, disease and death registers, service activity data and expert opinion [13]. In 
regard to the type of health care, the LYAR consists of three components:  
Total LYAR = LYAR of incidence + LYAR of disability + LYAR of mortality  (2) 
LYAR of incidence (LYAR(I)) for a disease or injury reflects health needs for primary prevention, 
which  equals  expected  incidence  of  an  uncomplicated  condition  multiplied  by  the  duration  of  the Int. J. Environ. Res. Public Health 2009, 6                 
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condition times the severity weight. Expected incidence includes two elements: prevented and observed 
incidences. Thus, 
LYAR(I) = expected incidence  duration  disability weight 
    = (prevented incidence + observed incidence)  duration  disability weight  
    = observed incidence  duration  disability weight / (1- (I))  
(3) 
where  attainment  (I)  =  prevented  incidences/(prevented  incidences  +  observed  incidences)  for  
0 ≤ attainment ≤ 1, under the assumption that the prevented cases would have the same duration and 
disability weight as the actual cases observed. The observed part of LYAR(I) could be estimated using 
the YLD for uncomplicated cases from the burden of disease studies. 
LYAR  of  disability  (LYAR(D))  represents  health  needs  for  secondary  prevention,  which  equals 
expected  incidence  of  a  disabling  complication  of  the  condition  multiplied  by  the  duration  of  the 
complication  times  the  disability  weight. For  a steady-state population, prevalence is approximately 
equal to incidence times duration [30]. The expected disability prevalence comprises two elements: 
prevented and observed disability prevalence. Thus,  
LYAR(D) = expected incidence of disabilities  duration  disability weight 
     = expected prevalence of disabilities  disability weight 
     = (prevented disabilities + observed disabilities)  disability weight  
       = observed disabilities  disability weight / (1- (D)) 
(4) 
where attainment (D) = prevented disabilities/(prevented disabilities + observed disabilities), assuming 
the prevented disabilities would have the same duration and disability weight as the actual disabilities 
observed. The observed LYAR(D) could be estimated using the YLD for complicated cases from the 
burden of disease studies. 
LYAR of mortality (LYAR(M)) describes health needs for tertiary prevention, which is the expected 
YLL attributable to the condition and incorporates two elements: prevented and observed YLL. Thus,  
LYAR(M) = expected YLL = (prevented YLL + observed YLL)  
      = observed YLL/(1- (M))  
(5) 
where attainment (M) = prevented YLL/(prevented YLL + observed YLL). The observed LYAR(M) 
could be estimated by the actual YLL from burden of disease studies. 
While observed LYAR can draw largely on information from burden of disease studies, prevented 
LYAR  is  less  directly  observable.  The  following  data  sources  may  be  helpful  for  estimating  these 
components:  
  Historical incidence, prevalence and mortality data; 
  Epidemiological expectation, for example, dengue fever and influenza incidences in a 
neighboring state of similar climate or global epidemic pattern; 
  Empirical estimation, for example, inferior health outcome in a neighboring population group 
without intervention; 
  Service activity data; 
  Risk factor analysis; and 
  Early detection and screening data. Int. J. Environ. Res. Public Health 2009, 6                 
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Burden of disease studies have been used to compare the health status of sub-groups within the 
population. If attainment (the proportion of prevented cases) is assumed to be equal across these sub-
groups, each group’s share of total LYAR will be the same as its share of total DALYs. It can be shown 
that: 
 
 





 
DALYs
DALYs
) - (1 LYAR   observed
) 1 ( LYAR   observed
LYAR)   observed LYAR   prevented (
LYAR)   observed LYAR   prevented (
LYAR   expected
LYAR   expected
Share   LYAR


  (6) 
where attainment =prevented LYAR/(prevented LYAR + actual LYAR). If, however, attainment is 
less in some population groups, for example, there is less access to services or a greater degree of 
unmet  needs,  the  DALY  will  be  oversensitive  to  negative  outcomes  for  these  groups.  This 
oversensitivity occurs because the actual LYAR prevented is smaller than that derived from uniform , 
and  the  sub-group’s  DALY  share  would  be  greater.  Table  2  gives  a  hypothetical  example  to 
demonstrate the rationale why the DALY is oversensitive to negative health outcomes. The total true 
amount of ill-health is shown by the expected LYAR (column 1) and its share (column 2). If not all 
members of groups A and C have access to preventive care, but all of Group B does (column 3), then 
assuming equal effectiveness of the care, a smaller proportion of life years will be prevented in groups A 
and C (column 4). The observed number of actual life years, as captured in the DALY (column 5), 
would be greater for groups A and C and their DALY share (column 6) greater than it would have been 
(column 2), had access to preventive care being equal across the groups. In this sense, the DALY is 
more generous to disadvantaged groups with inadequate access to health care services. 
 
Table 2. An hypothetical example (in life years, assuming effectiveness  = 50%). 
  Expected 
LYAR 
(‘000) 
LYAR share 
Treated 
LYAR 
(‘000) 
Prevented 
LYAR  
(‘000) 
Actual 
DALYs (‘000)  DALY share 
(1)  (2)  (3)  (4) = (3)    (5) = (1) – (4)  (6) 
Group A  30  5%  10  5  25  8% 
Group B  500  83%  500  250  250  76% 
Group C  70  12%  36  18  52  16% 
 
Existing  data  for  ischemic  heart  disease  (IHD)  and  type  2  diabetes  were  used  to  illustrate  the 
calculation  and  application  of  the LYAR.  For  IHD,  incidence  and mortality  data were taken from 
Australian  hospital  morbidity  and  mortality  databases  [31].  The  standard  life  expectancy  and  the 
disability weight for angina pectoris (0.105) were obtained from the 2003 Australian burden of disease 
study [32] with the expected duration by sex and age ranging from 2.4 to 24.5 years.  For type 2 
diabetes, the observed LYAR rates were derived from the Northern Territory (NT) and Australian 
burden of disease studies [32,33]. The disability weights and disease sequelae for type 2 diabetes were 
identical between the two studies.  Due to multiple data sources in burden of disease studies,  it was 
necessary to use DISMOD software to check and maintain the  internal plausibility and mathematical 
consistency  between  incidence,  prevalence,  mortality  and  duration  estimates  [34].  The  prevented Int. J. Environ. Res. Public Health 2009, 6                 
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component of LYAR was excluded as it only sought to demonstrate the split of LYAR by types of care 
for type 2 diabetes. The observed LYAR(I) was based upon uncomplicated cases of type 2 diabetes. 
The  LYAR(D)  was  derived  using  the  prevalence  of  retinopathy,  cataract,  glaucoma,  diabetic  foot, 
amputations, renal failure, neuropathy, peripheral vascular disease, IHD and stroke attributable to type 
2  diabetes.  The  LYAR(M)  was  determined  by  underlying  cause  of  death.  The  NT  Indigenous 
population for the period 1999–2003 was derived on the basis of the total estimated resident population 
(ERP) and the experimental Indigenous ERP [35,36]. The national population was the Australian ERP 
in  2003  [37].  The  rate  ratios  and  their  significances  were  inferred  by using conventional statistical 
methods [38].  
  
3. Results 
 
During 2001–2002, the observed IHD incidences in Australia were estimated to be 48,700 and the 
prevented incidences were about 12,000 (based on historical incidence level prior to intervention) [31]. 
This data generated an observed IHD LYAR(I) during 2001–2002 of 33,600 and a prevented LYAR(I) 
of 3,800. Thus, total LYAR(I) would be 37,400 and the attainment factor for IHD primary prevention 
about 20%. 
In  2006,  the  observed  number  of  actual  deaths  attributable  to  IHD  was  about  23,000  with  the 
prevented deaths approaching 73,000 [39]. This data generated an observed IHD LYAR(M) in 2006 of 
about 177,900 and a prevented LYAR(M) of 564,600. Thus, total IHD LYAR(M) in 2006 would be 
742,500 and the attainment factor for IHD tertiary prevention about 76%. 
 
Table 3. Observed life years at risk of type 2 diabetes per 1,000 population by age group 
and type of care, Northern Territory Indigenous population 1999–2003 vs Australia 2003. 
    NT Indigenous  Australia  Rate ratio 
      Male  Female  Male  Female  Male  Female 
LYAR (I) for primary prevention 
  0-29    4.9  8.0  0.2  0.5  28.9
*  17.6
* 
  30-49    17.4  21.5  6.4  5.1  2.7
*  4.2
* 
  50-69    18.5  20.5  9.5  7.9  2.0
*  2.6
* 
  70+    8.1  10.2  6.6  8.0  1.2  1.3 
  Total    9.0  12.6  4.4  4.1  2.0
*  3.1
* 
LYAR (D) for secondary prevention 
  0-29    2.7  2.4  0.0  0.0  1279.2
*  163.8
* 
  30-49    44.8  36.1  0.6  0.7  73.9
*  51.9
* 
  50-69    113.6  93.2  4.2  3.2  27.2
*  29.1
* 
  70+    49.7  42.7  9.7  9.7  5.1
*  4.4
* 
  Total    22.2  20.1  1.8  1.9  12.3
*  10.7
* 
LYAR (M) for tertiary prevention 
  0-29    0.2  0.4  0.0  0.0  134.9
*  113.6
* 
  30-49    18.4  15.8  0.5  0.3  38.6
*  58.6
* 
  50-69    76.3  69.8  6.9  3.0  11.0
*  23.6
* 
  70+    122.5  117.5  36.6  33.7  3.4
*  3.5
* 
  Total    12.4  13.0  4.5  4.2  2.8
*  3.1
* Int. J. Environ. Res. Public Health 2009, 6                 
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Table 3. Cont. 
LYAR for total health care 
  0-29    7.8  10.8  0.2  0.5  45.4
*  22.6
* 
  30-49    80.6  73.3  7.5  6.1  10.8
*  12.0
* 
  50-69    208.4  183.5  20.6  14.0  10.1
*  13.1
* 
  70+    180.3  170.3  52.9  51.4  3.4
*  3.3
* 
  Total    43.6  45.7  10.7  10.2  4.1
*  4.5
* 
Estimated resident population 
  0-29    94585  89180  4128384  3966432     
  30-49    33903  35809  2933508  2974180     
  50-69    11174  12808  2030435  2022961     
  70+    2109  2893  779315  1046254     
  Total    141771  140690  9871642  10009827     
Note: LYAR = life years at risk, I = Incidence, D = Disability, M = Mortality; NT = Northern Territory, Australia; 
* P < 0.01. 
 
The  next  example  demonstrates  the  application  of  observed  LYAR  on  type 2 diabetes. Table 3 
shows the type 2 diabetes rate ratios of NT Indigenous LYAR per 1000 population compared to the 
Australian average by age groups and three types of care. The total LYAR per 1000 population for both 
NT Indigenous males and females were over four times the Australian rates. At all levels (age group, 
gender and type of care), the observed LYAR per 1000 population for the NT Indigenous population 
was  greater  than  that  for  the  Australian  general  population.  The  differences  were  of  statistical 
significance (P < 0.01) except for LYAR(I) at ages 70 years and over. The rate ratios increased with 
descending age. The rate ratios for secondary prevention were greatest, over three times those for 
primary and tertiary prevention. The most striking differentials were in the age group 0–29 years for 
secondary and tertiary prevention.  
 
4. Discussion 
 
In line with the DALY, the LYAR measures the health needs of a defined population based on the 
probability  of  ill-health,  the  expected  duration  of  illness,  the  presence  of  disability  and  reduced  
longevity [40]. When comparing sub-groups within the population, the DALY share for groups with 
relatively poorer access to health care is likely to be higher than might otherwise be the case using 
LYAR, which considers the whole need (positive and negative health outcomes). Such amplification 
would give greater emphasis to their relative circumstances and may be desirable depending upon the 
purpose of the evaluation. If policy makers are seeking evidence to spend additional resources, then the 
DALY share will direct resources towards the population with more negative outcomes, but it will offer 
no insight about what type of care is needed. If policymakers are evaluating the effectiveness of current 
spending, LYARs may be the better measure. By including both prevented and observed instances, the 
LYAR provides insight into the remaining burden of disease as well as the achievements from on-going 
investments by types of care. Effective investments in prevention would be expected to lead to a lower 
DALY because they will lower incidence, disability and/or mortality. This does not, however, mean a 
lesser  need  for  health  services  if  on-going  services  are  required  to  maintain  the  current  level  of Int. J. Environ. Res. Public Health 2009, 6                 
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prevented cases. In contrast, the LYAR would not be affected because it shows the whole health need 
by including the prevented instances.  
The division of the LYAR according to the three types of health care would allow assessment of the 
relative contributions of pre-emptive, curative and life-saving interventions [41]. This dimension of the 
measure may be valuable for comparing the benefits of interventions in different sectors. It would also 
show the effect that interventions may have on other care types. Effective primary prevention may also 
reduce the LYAR for secondary and tertiary prevention because it lowers the occurrence of the disease. 
Effective secondary prevention (i.e. treatment of disease and injury) can reduce the LYAR for tertiary 
care. Capturing these dynamics could better inform on the relative impact of interventions in different 
care sectors.  
The prevention perspective of the LYAR can shift the focus beyond medical solutions and capture 
the impact on population health of other intercessions to improve education, employment, community 
infrastructure  and  other  socio-economic  factors,  including  poverty  and  the  social  and  economic 
participation  of  people  with  disabilities.  Furthermore,  the  LYAR  can  capture  improvements  in  the 
functionality of disabled persons by reassessing the disability weight to reflect the change in the level 
and sequelae of disability associated with a disease or injury. Although rehabilitative services improve 
quality of life and prevent premature death, they do not, however, prevent the condition. 
Health funding in Australia has largely overlooked mortality and morbidity [42]. This omission may 
be due to concerns that the mortality and DALY measures do not recognize the full needs for health 
care. The LYAR is a step toward an alternative measure that can more inform funding decisions by 
presenting a full picture of health needs.  
There  are  some  limitations  to  the  LYAR  measure.  First,  it  would  require  information  on  both 
observed  and  prevented  disease  and  injury.  Thus,  its  data  needs  are  considerable.  While  data  on 
observed cases may be available, estimating prevented cases may be more difficult as it may not be 
possible  to  readily  observe  their  numbers.  Historical  incidence  may  be  also  difficult  to  estimate 
accurately if appropriate and reliable records have not been kept. Second, LYAR will be vulnerable to 
errors in assumptions and interpretations of the occurrence and experience of disease and injury. For 
example,  rehabilitative  services  may  not  change  the  LYARs  if  the  disability  weights  only  reflect 
diagnoses,  not  functionality  and  quality  of  life.  Third,  the  LYAR  applies  the  concept  of  disability 
weights from the DALY so may be subject to similar criticisms to the DALY [18]. Further research is 
needed to consider the prospect of wider application and refinement of the population health needs 
measure that covers both positive and negative health outcomes.  
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